Database of advanced lung cancer patients with specific EGFR mutations in Asia
Official title: A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated Non-small Cell Lung Cancer (NSCLC)
Run by National Cancer Centre, Singapore · NCT06418412 · Data updated 2026-11-12
This study is gathering information from around 600 patients with advanced lung cancer and specific EGFR mutations in Asia to see how these mutations affect their treatment outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 21 Years to 99 Years |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | National Cancer Centre, Singapore Academic / other |
| Locations | 3 sites (Singapore and 2 other locations) |
| Status | Recruiting |
| Started | March 15, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | June 12, 2025 |
| Trial ID | NCT06418412 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults with histologically confirmed advanced NSCLC who have tested positive for EGFR exon 20 insertion mutations.
✕Probably not a fit
Patients without an EGFR exon 20 insertion mutation will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to gather comprehensive data on the epidemiology and clinical outcomes of patients with advanced non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertion mutations across various Asian countries. By enrolling approximately 600 patients from 20-30 sites, including major hospitals in Hong Kong, Korea, Singapore, Taiwan, and Thailand, the study seeks to understand how the specific location of the mutation may affect responses to targeted therapies. The data collected will help fill the existing knowledge gap regarding this specific mutation in the Asian population.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of advanced NSCLC patients with EGFR exon 20 insertion mutations, potentially enhancing treatment outcomes.
How similar studies have gone: While there is limited data on this specific mutation in Asia, similar studies on other EGFR mutations have shown promising results, indicating potential for success in this novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically confirmed advanced NSCLC 2. Positive testing result from any locally approved test (including but not limited to RT-PCR, Cobas and NGS) for EGFR exon 20 insertion mutation 3. Diagnosis date from 1 Jan 2013 to 31 Dec 2024 (to allow for minimum 12 months of follow-up clinical and treatment outcome data) 4. Male or female adults, age as defined by local regulations Exclusion Criteria: 1\. Patients without an EGFR exon 20 insertion mutation
Where it's running
-
National Cancer Centre, Singapore
Singapore, Singapore Recruiting -
Seoul National University Hospital
Seoul, South Korea Recruiting -
National Taiwan University Hospital
Taipei, Taiwan Recruiting
Study contacts
- Study coordinator: Cherlyn Shepherdson
- Email: cherlyn.shepherdson@nccs.com.sg
- Phone: +65 6306 1748
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.